website translator plugin
A Division of ViaDerma, Inc. , A Public Company.

Breakthrough Rapid Delivery of Nutrients and Medicines

  • image wide 1

APPLICATIONS & USAGE

We are developing products in the following fields of use;

Topical antibiotics

Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.

  • Estimated Global prevalence rate of all types of bacterial infection including pets: 2 Billion.
  • Estimated Global prevalence rate of MRSA: 140 million.
Topical toenail antifungal

Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.

Acne

The current state of the world acne market is overcrowded with generics and alternative therapies, such as photodynamic therapy and UV/blue light therapy. According to GlobalData's research, "the global acne market was worth $2.8 billion in 2009. It is estimated to reach revenues of $3.02 billion by 2016 at a Compound Annual Growth Rate (CAGR) of 0.7%. Estimated Global prevalence rate: 650 million.

Psoriasis

Psoriasis market is estimated to be worth about $2.4 billion. GIA announced the release of a comprehensive global report on Psoriasis drugs markets. The world market for psoriasis drugs is projected to exceed $7.3 billion by the year 2015. Estimated Global prevalence rate: 125 million.

Eczema

GlobalData estimated the global eczema therapeutics market to value $2.5B in 2014. It is expected to grow to a value of $3.8B by 2018, at a compound annual growth rate (CAGR) of 8.2%. Estimated Global prevalence rate: 700 million.

Anti-viral formula

Treats symptoms of Influenza which is a$4B/ year global market: Common

  • Estimated Global prevalence rate of Influenza: 355-1065 million.
  • Estimated Global prevalence rate of “Bird Flu”: Very rare, about 500 cases.
  • Estimated Global prevalence rate of “Swine Flu”: 1420 million were infected in 2009
Wound care

Diabetic foot wounds.

  • Diabetic foot Ulcers; $1.5B/year global market. 12 million people per year

Contact Details

ViaDerma's global headquarters is located at
8950 W. Olympic Blvd, Suite 576, Beverly Hills, CA 90211.

We are currently in discussions with companies in Australia & New Zealand, India, China, and West Africa.

Phone: 310.871.3996